What Листата treats: Main Uses and Benefits

Листата (Orlistat) is commonly used to help with symptomatic support during comprehensive weight management efforts. Its use is relevant in clinical contexts involving heightened systemic burden, where supportive symptom management is appropriate.

The medication is commonly used to address the conditions of obesity and overweight when patients have co-existing health risk factors, such as high blood pressure or high cholesterol. It may assist with achieving clinically significant weight reduction and is applied for the chronic management of weight stability to address the challenge of weight regain.

“It supports maintenance of a healthier body weight, which may assist with easing the potential for metabolic and physical strain associated with weight fluctuations.”

By contributing to weight management, the application is relevant in conditions marked by increased physiological stress, such as metabolic disturbances (including issues with blood fat and glucose levels) that may accompany obesity. It supports patients by easing the overall symptom load and may assist with maintaining functional stability relevant to overall well-being during symptomatic phases.

---

Quick Fact: Relief for Excess Body Weight
Used across domains where supportive symptom management for clinically significant overweight and obesity is appropriate.

Regulatory References

1. NIH StatPearls overview

Eligibility for Листата (Orlistat) — Official Regulatory Information

Contraindicated Populations

Use of Листата is strictly contraindicated in several patient populations, as mandated by regulatory agencies. Individuals must not use the medicine if they have a known Hypersensitivity (allergy) to orlistat or any of its components. Absolute contraindications also include pre-existing gastrointestinal or liver conditions such as Chronic Malabsorption Syndrome and Cholestasis.

Age and Reproductive Status

The approved eligibility for use is determined by age and formulation strength. The prescription strength (120 mg) is approved for adolescents aged 12 years and older. The over-the-counter (OTC 60 mg) product is approved for use only in adults aged 18 years and older. Furthermore, the medicine is contraindicated in women who are pregnant and in those who are breastfeeding.

Condition-Based Restrictions

Official labeling defines restricted use requiring caution for patients with certain comorbidities. This includes individuals with a history of Hyperoxaluria or calcium oxalate Nephrolithiasis (kidney stones) due to potential risks. Patients with Diabetes or Hypothyroidism also require careful monitoring, as weight loss may necessitate adjustments to their existing medication dosages.

Concomitant Restrictions

Use is contraindicated for patients taking certain medications, most notably Ciclosporin (Cyclosporine), due to the risk of reduced absorption of the concomitant drug.

Interactions with other medicines and products

Листата’s interaction profile is primarily governed by its role as a substrate and inhibitor of the Cytochrome P450 (CYP) 3A4 enzyme and the P-glycoprotein (P-gp) transporter. These pharmacokinetic mechanisms can significantly alter the concentration of Листата or other co-administered medicines, leading to a risk of either reduced effectiveness or increased side effects.

Interacting Product Category	Regulatory Classification	Mechanism & Effect
Strong CYP3A4 Inducers (e.g., Rifampicin)	Contraindicated	Causes significant decrease in Листата plasma levels, risking loss of therapeutic effect.
Strong/Moderate CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)	Requires Dose Adjustment	Causes clinically significant increase in Листата plasma levels, requiring a mandated 50% dose reduction.
QT-Prolonging Agents (e.g., Amiodarone)	Use Not Recommended	Pharmacodynamic interaction with additive effect on the QT interval, increasing risk of cardiac arrhythmia.
P-gp Substrates (e.g., Digoxin)	Caution/Monitoring	Листата may inhibit P-gp, increasing the plasma concentration of the substrate. Monitoring and dose adjustment may be necessary.

Co-administration with other medications known to cause hypotension may lead to additive blood pressure-lowering effects. When considering combination use, healthcare professionals rely on official labeling to classify the interaction risk, which ranges from strictly contraindicated combinations to those requiring caution or dose modifications based on the mechanistic data.

Covalent Lipase Inhibition and Non-Systemic Action

Листата's mechanism operates exclusively in the gastrointestinal lumen by targeting the digestive enzymes gastric lipase and pancreatic lipase. Its active ingredient, Orlistat, forms a stable, covalent bond with a specific serine residue at the enzyme's active site, rendering the lipases inactive. This non-systemic mechanism ensures the drug’s pharmacological effect is localized to the gut, without significant absorption into the bloodstream.

Interruption of Fat Digestion

This enzymatic blockade directly halts the fat hydrolysis pathway. The lipases are prevented from performing their physiological function of breaking down large dietary fats (triglycerides) into smaller, absorbable molecules (free fatty acids and monoglycerides). This interruption of the digestive cascade dictates that a portion of the ingested fat remains whole and cannot be taken up by the body.

Modulation of Caloric Input

The consequence of undigested fat is its subsequent excretion in the feces. The clearance of non-absorbed fat results in a lower systemic energy yield from the consumed diet. A direct mechanistic consequence is the concurrent impaired absorption of certain lipophilic nutrients (e.g., vitamins A, D, E, and K), as their uptake is intrinsically linked to the fat digestion pathway.

The administration of Листата (Orlistat) follows a precise, structured oral protocol synchronized with the patient's dietary habits. The medication is supplied in hard capsules for oral administration and is provided in two primary strengths: 120 mg for prescription use and 60 mg for non-prescription use.

The standard adult regimen for both the 60 mg and 120 mg strengths is one capsule, three times a day. The maximum recommended daily administration is 360 mg. Administration must be strictly timed: the dose should be taken immediately before, during, or up to one hour after each main meal that contains fat. A core instruction is to omit the dose entirely if a meal is missed or contains no fat, which reinforces the drug’s meal-dependent usage pattern.

Administration Requirements

Treatment is defined as an adjunctive therapy, requiring simultaneous adherence to a nutritionally balanced, reduced-calorie diet in which approximately 30% of total daily calories are derived from fat.

• Pediatric Use: The 120 mg dose may be used in pediatric patients aged 12 years and older.
• Supplement Timing: Due to potential impacts on fat-soluble vitamins, a multivitamin supplement must be taken at least two hours apart from the Orlistat dose, typically at bedtime.
• Duration: For the prescription strength, therapy is discontinued if the patient has not achieved at least a 5% reduction in initial body weight after 12 weeks of continuous use.

Research evidence / Overview of Studies for Листата (Orlistat)

---

Evidence for Use in Comprehensive Management of Overweight and Obesity

Research examined how outcomes related to systemic or functional imbalance might change during the study period by utilizing large-scale, randomized controlled trials (RCTs). These trials were used to evaluate the use of Orlistat in adults with obesity or those who were overweight and had other health risk factors. Studies monitored changes measured in total body weight and Body Mass Index (BMI) over the short term (typically up to one year).

Data show patterns related to the number of participants who reached key outcomes, such as losing 5% or more of their initial body weight, in the groups receiving the medication versus those receiving placebo. What remains uncertain is the variability of response between different people; research does not determine whether an individual will respond similarly, and results apply only to the populations studied.

---

Evidence Related to Long-Term Weight Management and Regain Prevention

The research landscape includes extended-duration clinical trials, often lasting up to four years, which was studied for chronic weight management and stability. Researchers monitored outcomes related to systemic or functional imbalance by measuring whether the weight lost was maintained over the multi-year observation period.

Studies monitored how symptoms evolved in the observed populations. Findings indicate patterns where the measurement of time to weight regain was observed in some studies to be different in the group continuing the medication compared to the group receiving placebo. A key limitation is that follow-up durations were limited to about four years, and there is limited information for long-term outcomes beyond this period.

---

Evidence Regarding Associated Metabolic Risk Factors

Orlistat was evaluated in studies focusing on specific subgroups of patients with obesity who also had associated metabolic concerns, such as impaired glucose tolerance or high cholesterol/blood fat levels (dyslipidemia). Research examined the long-term measurement of the incidence of new Type 2 Diabetes diagnoses over four years. Research describes patterns where the observed changes in metabolic markers were seen in parallel with the measured weight reduction.

---

What is Still Uncertain or Under Research Regarding Листата

• Long-term effects are not fully established beyond the four-year study periods for chronic weight management. The evidence is limited on the stability of the response over periods exceeding this duration.
• The results apply only to the populations studied, and the data for children and adolescents remain insufficient in both size and duration.
• Study results reflect the specific conditions under which they were conducted and do not provide a guarantee of individual outcomes. Findings describe group patterns, not personal outcomes.

Key Studies & References

1. Orlistat - NIH StatPearls

Common questions about Листата (FAQ)

Q: Does Листата start working immediately or does it take a while?

Official product information states that the drug's mechanism of increased fat excretion is often measurable within 24 to 48 hours of the first dose. However, based on clinical studies, statistically significant and measurable weight reduction typically takes over two months to be observed. Results described in official documents highlight that individual responses may vary.

---

Q: What happens if I forget to take Листата one time?

Official product instructions state that if a dose is forgotten, it may be taken as soon as it is remembered, if it is still within one hour of the main meal. If more than an hour has passed, it is indicated that the dose should be omitted entirely, and the individual may return to the regular dosing schedule with the next meal. This procedure reflects the drug's meal-dependent action.

---

Q: Can people with high blood pressure use Листата?

High blood pressure (hypertension) is not listed as a strict contraindication in regulatory documents for this medicine. However, official guidance notes that patients with co-occurring health conditions may require close monitoring by a healthcare professional. Weight reduction may necessitate adjustments to a patient's existing medication regimen.

---

Q: Are there special considerations for children taking Листата?

Regulatory authorities have approved the prescription strength of 120 mg for use in adolescents aged 12 years and older. Official documents emphasize that research evidence on safety and effectiveness is currently limited for children younger than 12 years of age.

---

Q: How long do most people stay on Листата?

The duration of therapy is determined by an individual's response and the prescribing professional’s assessment. Clinical trials have examined the drug’s use for periods up to four years. Discontinuation criteria described in official documents include failure to achieve a minimum 5% weight loss goal after 12 weeks of use.

---

Q: If I stop taking Листата, are there any expected effects?

Official information indicates that the drug’s direct effect on fat excretion typically ceases within 48 to 72 hours of the last dose. The drug's impact on fat absorption generally ceases within this timeframe. Clinical studies focused on long-term weight management monitored for the potential of weight regain upon discontinuation of the medicine.

---

Q: What if the side effects of Листата don't go away?

Regulatory documents indicate that the incidence of common gastrointestinal side effects often lessens with prolonged use and adherence to a low-fat diet. If these side effects persist over time or cause significant discomfort, official information advises consulting a healthcare professional.

---

Q: What kind of monitoring (tests) is needed while on Листата?

Monitoring typically involves regularly checking body weight, body mass index (BMI), and lipid profile. Official product information indicates that for patients using certain co-administered medications, additional laboratory checks are specified, such as measuring drug levels or assessing bleeding risk (INR).

---

Q: Is there a specific maximum length of time Листата is meant to be used?

There is no regulatory-mandated maximum duration specified in the official product information. Clinical research has primarily examined the long-term use of the medicine for periods up to four years.

---

Q: Is it normal to feel tired when you first start taking Листата?

Official regulatory documents list fatigue, which is an unusual tiredness or weakness, as a common side effect of the medicine. Patients who experience persistent fatigue are advised in patient labeling to consult their healthcare professional.

---

Q: Can Листата be taken with over-the-counter pain relievers?

Based on official interaction data, no known specific drug-drug interaction has been identified between this medicine and over-the-counter acetaminophen (paracetamol). Official patient guidance indicates that individuals should discuss the combination of any medicines or supplements with their healthcare provider.

---

Q: Is it okay to drink alcohol while using Листата?

The official patient information indicates that alcohol is not expected to interact directly with the medicine. Official patient information recommends that individuals discuss alcohol consumption habits with a healthcare provider.

---

Q: Can Листата cause mood changes or depression?

Regulatory safety information lists both anxiety and depression as common psychiatric side effects of the medicine. Sleep disorder is also included in this category of common effects.

---

Q: Is there a generic version of Листата available?

The active ingredient is Orlistat, which is sold under various brand names, including prescription and over-the-counter formulations. The development of generic versions is addressed in regulatory guidance documents, and the drug is available under its non-branded name.

---

Q: Can I drive or operate machinery while taking Листата?

Official patient information indicates that caution is advised regarding driving or operating machinery until the individual is aware of how the medicine affects them. Dizziness is listed as a reported side effect, which could potentially impair the ability to drive safely.

---

Q: Does Листата interact with herbal supplements?

Official patient guidance states that a healthcare professional should be informed about the use of all products, including herbal supplements, vitamins, and over-the-counter medicines, in order to review the full patient regimen.

---

Q: Is it normal for the color of my urine to change when taking Листата?

A simple, benign change in urine color is not listed as a common or expected side effect in official documents. However, dark urine is listed in the safety information as a potential sign of a serious liver problem and is listed as a sign of a serious medical issue that requires urgent consultation.

---

Q: Can Листата affect my sleep?

Regulatory safety information lists sleep disorder as a common side effect of the medicine. This effect is included under the category of psychiatric effects documented in the official labeling.

---

Q: Does taking a large dose of Листата accidentally cause major problems?

Reports of accidental overdose suggest that patients are often asymptomatic or experience side effects similar to those that occur with the recommended dose. Official safety information notes that observation for at least 24 hours may be recommended following a significant overdose.

---

Q: Can Листата be used by people who have had cancer?

Official regulatory contraindications do not explicitly include a history of cancer. However, specific medical conditions or treatments related to cancer may necessitate individual monitoring or caution. This factor may require consultation with a specialist.

---

Q: How quickly does Листата leave the body after the last dose?

While the exact pharmacokinetic half-life is not usually detailed in patient information, the drug's effect on fecal fat excretion is generally observed to cease and return to normal levels within 48 to 72 hours after the last dose is taken.

How to Store and Dispose of Листата (Orlistat)

The medicine must be stored strictly according to regulatory conditions to ensure product quality and safety.

Storage & Disposal Requirement	Official Regulatory Statement
Labeled Temperature	Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). Do not freeze.
Protection & Container	Keep the medicine in the original container, which must be tightly closed, to protect from moisture [Source: FDA/MedlinePlus Labeling].
Child Safety	Mandatory instruction: Keep out of the sight and reach of children [Source: EMA/FDA Labeling].
Disposal Instructions	Do not dispose of unused or expired medicine via wastewater or household waste. Ask a pharmacist for the proper method for discarding the product [Source: EMA SmPC].

These instructions define the constraints for storage and handling, requiring the product to be maintained under specific temperature and environmental conditions and ensuring safe management of pharmaceutical waste.